BCL2L1 and acute myeloid leukemia: For instance, in Kasumi-1 and KG-1α AML cell lines, treatment with the DGKα-specific inhibitor ritanserin resulted in significant inhibition of the phospholipase D–PA–sphingosine kinase 1 axis, suppression of the JAK–STAT and MAPK pathways, and downregulation of PARP, caspase-3, MCL1, and Bcl-xL.